RS64263B1 - Stabilna anti-ifnar1 formulacija - Google Patents
Stabilna anti-ifnar1 formulacijaInfo
- Publication number
- RS64263B1 RS64263B1 RS20230447A RSP20230447A RS64263B1 RS 64263 B1 RS64263 B1 RS 64263B1 RS 20230447 A RS20230447 A RS 20230447A RS P20230447 A RSP20230447 A RS P20230447A RS 64263 B1 RS64263 B1 RS 64263B1
- Authority
- RS
- Serbia
- Prior art keywords
- ifnar1
- formulation
- stable anti
- stable
- ifnar1 formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562207164P | 2015-08-19 | 2015-08-19 | |
EP20174805.0A EP3769781B1 (en) | 2015-08-19 | 2016-08-18 | Stable anti-ifnar1 formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
RS64263B1 true RS64263B1 (sr) | 2023-07-31 |
Family
ID=58052002
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20201103A RS60773B1 (sr) | 2015-08-19 | 2016-08-18 | Stabilna anti-ifnar1 formulacija |
RS20230447A RS64263B1 (sr) | 2015-08-19 | 2016-08-18 | Stabilna anti-ifnar1 formulacija |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20201103A RS60773B1 (sr) | 2015-08-19 | 2016-08-18 | Stabilna anti-ifnar1 formulacija |
Country Status (24)
Country | Link |
---|---|
US (1) | US10125195B2 (sr) |
EP (3) | EP4233892A3 (sr) |
JP (3) | JP6720293B2 (sr) |
KR (4) | KR102669174B1 (sr) |
CN (1) | CN107921109A (sr) |
AU (3) | AU2016308262C1 (sr) |
BR (1) | BR112018002196A8 (sr) |
CA (1) | CA2995222C (sr) |
CY (2) | CY1123657T1 (sr) |
DK (2) | DK3769781T3 (sr) |
ES (2) | ES2947488T3 (sr) |
FI (1) | FI3769781T3 (sr) |
HK (1) | HK1256195A1 (sr) |
HR (2) | HRP20230463T1 (sr) |
HU (2) | HUE061985T2 (sr) |
IL (1) | IL257279B2 (sr) |
LT (2) | LT3337502T (sr) |
PL (2) | PL3769781T3 (sr) |
PT (2) | PT3337502T (sr) |
RS (2) | RS60773B1 (sr) |
RU (1) | RU2731737C2 (sr) |
SG (1) | SG10202106970XA (sr) |
SI (2) | SI3769781T1 (sr) |
WO (1) | WO2017031288A1 (sr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017031288A1 (en) | 2015-08-19 | 2017-02-23 | Medimmune, Llc | Stable anti-ifnar1 formulation |
GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
US20200061015A1 (en) * | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
EP4058060A1 (en) * | 2019-11-11 | 2022-09-21 | Astrazeneca AB | Type i interferon inhibition in systemic lupus erythematosus |
CN115667309A (zh) | 2020-05-29 | 2023-01-31 | 阿斯利康(瑞典)有限公司 | 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病 |
KR20230026490A (ko) | 2020-06-25 | 2023-02-24 | 메디뮨 리미티드 | 아밀로이드 베타 1-42에 결합하는 항체를 이용한 축삭 손상의 예방 |
TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
CN117157099A (zh) * | 2021-04-23 | 2023-12-01 | 阿斯利康(瑞典)有限公司 | 用于皮下注射的抗ifnar1给药方案 |
MX2023012465A (es) | 2021-04-23 | 2024-04-04 | Astrazeneca Ab | Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. |
EP4192882A1 (en) * | 2021-04-23 | 2023-06-14 | Astrazeneca AB | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
KR20240000557A (ko) * | 2021-04-23 | 2024-01-02 | 아스트라제네카 아베 | 피부 홍반 루푸스의 치료 |
AU2022274306A1 (en) * | 2021-05-12 | 2023-11-23 | Astrazeneca Ab | Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients |
WO2023284073A1 (zh) * | 2021-07-13 | 2023-01-19 | 江苏荃信生物医药股份有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂 |
CN113521276B (zh) * | 2021-07-13 | 2022-04-12 | 江苏荃信生物医药股份有限公司 | 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂 |
CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
AU2022317215A1 (en) | 2021-07-27 | 2024-02-29 | Astrazeneca Ab | Treatment of lupus |
AU2022359684A1 (en) * | 2021-10-04 | 2024-05-09 | Astrazeneca Ab | Treatment of lupus |
CA3234358A1 (en) * | 2021-10-29 | 2023-05-04 | Intas Pharmaceuticals Ltd. | Stable lyophilized formulation of an anti-.alpha.4.beta.7 antibody |
TW202337497A (zh) * | 2022-02-18 | 2023-10-01 | 中國大陸商重慶明道浩悅生物科技有限公司 | 鼻內調配物及抗sars-cov-2棘蛋白抗體 |
WO2024009205A1 (en) * | 2022-07-06 | 2024-01-11 | Intas Pharmaceuticals Ltd. | STABLE LIQUID FORMULATION OF AN ANTI-Α4ß7 ANTIBODY |
WO2024079241A1 (en) | 2022-10-13 | 2024-04-18 | Astrazeneca Ab | Treatment of lupus |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
EP2662390B1 (en) * | 2004-06-21 | 2017-08-02 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2094729A1 (en) * | 2006-12-11 | 2009-09-02 | F.Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
KR101666229B1 (ko) | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Fc 리간드 친화성이 감소된 항-IFNAR1 항체 |
CN102438652B (zh) | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
CA2849192C (en) * | 2011-10-12 | 2019-09-24 | Ascendis Pharma Ophthalmology Division A/S | Prevention and treatment of ocular conditions |
MX352823B (es) | 2011-10-28 | 2017-12-04 | Integritybio Inc | Formulaciones de proteinas que contienen aminoacidos. |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
BR112015008186A2 (pt) * | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
JP2016519145A (ja) * | 2013-05-15 | 2016-06-30 | メディミューン リミテッド | 組換え産生ポリペプチドの精製 |
CA2923859C (en) * | 2013-09-11 | 2021-11-23 | Arsia Therapeutics, Inc. | Liquid protein formulations containing viscosity-lowering agents |
WO2015063180A1 (en) * | 2013-10-29 | 2015-05-07 | Novozymes Biopharma Dk A/S | Antibody composition |
RU2017107847A (ru) | 2014-09-03 | 2018-10-03 | Медиммун Лимитед | Стабильный состав на основе антитела к il-4r-альфа |
WO2016109822A1 (en) | 2014-12-31 | 2016-07-07 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
WO2017031288A1 (en) | 2015-08-19 | 2017-02-23 | Medimmune, Llc | Stable anti-ifnar1 formulation |
-
2016
- 2016-08-18 WO PCT/US2016/047506 patent/WO2017031288A1/en active Application Filing
- 2016-08-18 SG SG10202106970XA patent/SG10202106970XA/en unknown
- 2016-08-18 AU AU2016308262A patent/AU2016308262C1/en active Active
- 2016-08-18 DK DK20174805.0T patent/DK3769781T3/da active
- 2016-08-18 PL PL20174805.0T patent/PL3769781T3/pl unknown
- 2016-08-18 PL PL16837818T patent/PL3337502T3/pl unknown
- 2016-08-18 EP EP23160045.3A patent/EP4233892A3/en active Pending
- 2016-08-18 RU RU2018107725A patent/RU2731737C2/ru active
- 2016-08-18 CN CN201680047012.7A patent/CN107921109A/zh active Pending
- 2016-08-18 KR KR1020207029325A patent/KR102669174B1/ko active IP Right Grant
- 2016-08-18 BR BR112018002196A patent/BR112018002196A8/pt active Search and Examination
- 2016-08-18 HU HUE20174805A patent/HUE061985T2/hu unknown
- 2016-08-18 FI FIEP20174805.0T patent/FI3769781T3/fi active
- 2016-08-18 RS RS20201103A patent/RS60773B1/sr unknown
- 2016-08-18 KR KR1020247016705A patent/KR20240090616A/ko active Search and Examination
- 2016-08-18 EP EP20174805.0A patent/EP3769781B1/en active Active
- 2016-08-18 HU HUE16837818A patent/HUE051862T2/hu unknown
- 2016-08-18 EP EP16837818.0A patent/EP3337502B1/en active Active
- 2016-08-18 ES ES20174805T patent/ES2947488T3/es active Active
- 2016-08-18 PT PT168378180T patent/PT3337502T/pt unknown
- 2016-08-18 US US15/240,224 patent/US10125195B2/en active Active
- 2016-08-18 SI SI201631699T patent/SI3769781T1/sl unknown
- 2016-08-18 DK DK16837818.0T patent/DK3337502T3/da active
- 2016-08-18 SI SI201630900T patent/SI3337502T1/sl unknown
- 2016-08-18 KR KR1020187007314A patent/KR102168005B1/ko active IP Right Grant
- 2016-08-18 KR KR1020227031079A patent/KR20220127378A/ko not_active Application Discontinuation
- 2016-08-18 HR HRP20230463TT patent/HRP20230463T1/hr unknown
- 2016-08-18 LT LTEP16837818.0T patent/LT3337502T/lt unknown
- 2016-08-18 ES ES16837818T patent/ES2818229T3/es active Active
- 2016-08-18 IL IL257279A patent/IL257279B2/en unknown
- 2016-08-18 PT PT201748050T patent/PT3769781T/pt unknown
- 2016-08-18 RS RS20230447A patent/RS64263B1/sr unknown
- 2016-08-18 CA CA2995222A patent/CA2995222C/en active Active
- 2016-08-18 LT LTEP20174805.0T patent/LT3769781T/lt unknown
- 2016-08-18 JP JP2018508149A patent/JP6720293B2/ja active Active
-
2018
- 2018-11-29 HK HK18115287.0A patent/HK1256195A1/zh unknown
-
2020
- 2020-05-21 AU AU2020203306A patent/AU2020203306C1/en active Active
- 2020-06-17 JP JP2020104494A patent/JP7035119B2/ja active Active
- 2020-08-19 HR HRP20201297TT patent/HRP20201297T1/hr unknown
- 2020-09-11 CY CY20201100860T patent/CY1123657T1/el unknown
-
2021
- 2021-10-26 AU AU2021257915A patent/AU2021257915A1/en active Pending
-
2022
- 2022-03-02 JP JP2022031581A patent/JP2022066345A/ja active Pending
-
2023
- 2023-06-20 CY CY20231100289T patent/CY1126062T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256195A1 (zh) | 穩定的抗ifnar1配製品 | |
GB201513010D0 (en) | Novel formulation | |
GB201407934D0 (en) | Formulation | |
GB201514758D0 (en) | Formulation | |
GB201608356D0 (en) | Formulation | |
RS62057B1 (sr) | Formulacija maropitanta | |
IL248835B (en) | A preparation of ciritinib | |
GB201407384D0 (en) | Formulation | |
IL251362A0 (en) | formulation | |
GB201521771D0 (en) | Formulation | |
GB201511255D0 (en) | Formulation | |
GB201509891D0 (en) | Formulation | |
GB201707615D0 (en) | Formulation | |
GB201511301D0 (en) | Formulation | |
PL3559185T3 (pl) | Preparat nabłyszczający | |
GB201609925D0 (en) | Formulation | |
GB201514014D0 (en) | Formulation | |
GB201602048D0 (en) | Formulation | |
GB201504662D0 (en) | Formulation | |
GB201508527D0 (en) | Novel formulation | |
GB201507784D0 (en) | Formulations | |
GB201505532D0 (en) | Formulations | |
GB201416536D0 (en) | Formulation | |
GB201416274D0 (en) | Formulation | |
GB201412754D0 (en) | Formulation |